These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6761111)

  • 1. In vitro stimulation of Bacteroides fragilis growth by Escherichia coli.
    Hagen JC; Wood WS; Hashimoto T
    Eur J Clin Microbiol; 1982 Dec; 1(6):338-43. PubMed ID: 6761111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic lethality in experimental infections with Escherichia coli and Bacteroides fragilis.
    Rodloff AC; Hahn H
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Oct; 258(1):112-9. PubMed ID: 6395577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early events after intra-abdominal infection with Bacteroides fragilis and Escherichia coli.
    Verweij WR; Namavar F; Schouten WF; MacLaren DM
    J Med Microbiol; 1991 Jul; 35(1):18-22. PubMed ID: 2072375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of short-chain fatty acids on in vitro bacterial growth of Bacteroides fragilis and Escherichia coli.
    Mortensen FV; Møller JK; Hessov I
    APMIS; 1999 Feb; 107(2):240-4. PubMed ID: 10225323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrin in peritonitis. IV. Synergistic intraperitoneal infection caused by Escherichia coli and Bacteroides fragilis within fibrin clots.
    Dunn DL; Rotstein OD; Simmons RL
    Arch Surg; 1984 Feb; 119(2):139-44. PubMed ID: 6365029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ampicillin and ampicillin-sulbactam dilution tests with mixed cultures of Bacteroides fragilis, Escherichia coli and Enterococcus.
    Heilmann F
    Infection; 1993; 21(3):187-90. PubMed ID: 8365818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quantitative and histological demonstration of pathogenic synergy between Escherichia coli and Bacteroides fragilis in guinea-pig wounds.
    Kelly MJ
    J Med Microbiol; 1978 Nov; 11(4):513-23. PubMed ID: 364068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Predominance of Bacteroides of the fragilis group in the fecal flora under the influence of gentamycin and kanamycin].
    García Sánchez JE; Martín Luengo F; Prieto Prieto J; Rodrigo Sánchez N
    Rev Clin Esp; 1978 Jul; 150(1-2):77-80. PubMed ID: 360322
    [No Abstract]   [Full Text] [Related]  

  • 9. The spectrum of Escherichia coli--Bacteroides fragilis pathogenic synergy in an intraabdominal infection model.
    Rotstein OD; Kao J
    Can J Microbiol; 1988 Mar; 34(3):352-7. PubMed ID: 3046726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice.
    Brook I
    J Infect Dis; 1989 Oct; 160(4):651-6. PubMed ID: 2677161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of cefuroxime and cefotaxime by Bacteroides fragilis in vitro, and its influence on the treatment of an experimental Escherichia coli/Bacteroides fragilis mixed infection.
    Beale AS; Gisby J
    J Antimicrob Chemother; 1989 Jul; 24(1):29-37. PubMed ID: 2674099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Escherichia coli and Bacteroides fragilis on peritoneal host defenses.
    Dunn DL; Barke RA; Ewald DC; Simmons RL
    Infect Immun; 1985 May; 48(2):287-91. PubMed ID: 3886544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
    Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
    Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal synergy between Escherichia coli and Bacteroides fragilis in an intra-abdominal infection model.
    Rotstein OD; Kao J; Houston K
    J Med Microbiol; 1989 Aug; 29(4):269-76. PubMed ID: 2668529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vivo bactericidal activity of Sch 34343 in Bacteroides fragilis abscesses and in Bacteroides fragilis-Escherichia coli abscesses.
    Wells CL; Arland LA; Simmons RL; Rotstein OD
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():199-206. PubMed ID: 3897172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of amoxycillin and benzylpenicillin combined with clavulanic acid against Bacteroides fragilis in vitro and in experimentally infected mice.
    Dijkmans BA; Vaishnav J; Mattie H
    Scand J Infect Dis; 1985; 17(3):311-21. PubMed ID: 3903976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro bactericidal activities and morphologic changes in Escherichia coli and Bacteroides fragilis by cephalosporins.
    Mikamo H; Kawazoe K; Sato Y; Hayasaki Y; Satoh M; Kai J; Tamaya T
    Chemotherapy; 1998; 44(3):157-63. PubMed ID: 9612605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of ceftriaxone in experimental infections involving Bacteroides fragilis and Escherichia coli.
    Dezfulian M; Bitar RA; Bartlett JG
    Chemotherapy; 1993; 39(5):355-60. PubMed ID: 8370326
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenicity of capsulate and non-capsulate members of Bacteroides fragilis and B. melaninogenicus groups in mixed infection with Escherichia coli and Streptococcus pyogenes.
    Brook I
    J Med Microbiol; 1988 Nov; 27(3):191-8. PubMed ID: 2903934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dynamics of intraperitoneal growth and elimination of Escherichia coli and Bacteroides fragilis in porcine faecal peritonitis treated with fosfomycin.
    Berglund J; Andåker L; Skau T; Nyström PO
    J Antimicrob Chemother; 1991 Apr; 27(4):527-33. PubMed ID: 1856131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.